CA2375033A1 - Vaccines against conformation-dependent antigens and against antigens that are not or are not only proteins or peptides - Google Patents

Vaccines against conformation-dependent antigens and against antigens that are not or are not only proteins or peptides Download PDF

Info

Publication number
CA2375033A1
CA2375033A1 CA002375033A CA2375033A CA2375033A1 CA 2375033 A1 CA2375033 A1 CA 2375033A1 CA 002375033 A CA002375033 A CA 002375033A CA 2375033 A CA2375033 A CA 2375033A CA 2375033 A1 CA2375033 A1 CA 2375033A1
Authority
CA
Canada
Prior art keywords
peptides
antigen
conformation
dna
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002375033A
Other languages
English (en)
French (fr)
Inventor
Steffen Goletz
Uwe Karsten
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Delbrueck Centrum fuer Molekulare in der Helmholtz Gemeinschaft
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2375033A1 publication Critical patent/CA2375033A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CA002375033A 1999-05-27 2000-05-29 Vaccines against conformation-dependent antigens and against antigens that are not or are not only proteins or peptides Abandoned CA2375033A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE19924405.7 1999-05-27
DE19924405 1999-05-27
DE19943016 1999-09-09
DE19943016.0 1999-09-09
PCT/DE2000/001809 WO2000073430A2 (de) 1999-05-27 2000-05-29 Vakzine gegen konformationsabhängige antigene sowie gegen antigene, die keine oder nicht ausschliesslich proteine oder peptide sind

Publications (1)

Publication Number Publication Date
CA2375033A1 true CA2375033A1 (en) 2000-12-07

Family

ID=26053552

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002375033A Abandoned CA2375033A1 (en) 1999-05-27 2000-05-29 Vaccines against conformation-dependent antigens and against antigens that are not or are not only proteins or peptides

Country Status (5)

Country Link
EP (1) EP1181058A2 (de)
AU (1) AU6424300A (de)
CA (1) CA2375033A1 (de)
DE (1) DE10027695A1 (de)
WO (1) WO2000073430A2 (de)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US8030025B2 (en) 2008-02-20 2011-10-04 Amgen Inc. Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
US8642276B2 (en) * 2002-07-22 2014-02-04 Glycotope Gmbh Method for the production of an immunostimulating mucin (MUC1)
US20140206021A1 (en) * 2002-12-03 2014-07-24 North Carolina State University Prion protein ligands and methods of use

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7109308B1 (en) 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US7153827B1 (en) 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
JPH09510093A (ja) 1994-03-08 1997-10-14 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 血管内皮細胞増殖因子２
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US6040157A (en) 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
MXPA02003434A (es) 2000-08-04 2002-09-02 Human Genome Sciences Inc Factor de crecimiento endotelial vascular 2.
US7402312B2 (en) 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
DK1385864T3 (da) * 2001-04-13 2010-08-16 Human Genome Sciences Inc Anti-VEGF-2-antistoffer
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
CA2490280A1 (en) 2002-07-01 2004-01-08 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
GB0324265D0 (en) * 2003-10-16 2003-11-19 Medical Res Council Peptide
CN103130895A (zh) 2004-03-29 2013-06-05 阿伯丁大学理事会 抗突触泡蛋白的特异结合成员
EP1871882A1 (de) * 2005-03-25 2008-01-02 GlycArt Biotechnology AG Auf mcsp gerichtete antigenbindende moleküle mit erhöhter fc-rezeptor-bindungsaffinität und effektorfunktion
EP2172484A3 (de) 2005-05-18 2010-05-19 Ablynx N.V. Serum Albumin bindende Proteine
DE102005023617A1 (de) 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
CN1301267C (zh) * 2005-06-21 2007-02-21 中国人民解放军军事医学科学院附属医院 Muc1粘蛋白的一个模拟表位肽及其编码dna与应用
DK2245052T3 (en) 2008-01-25 2017-09-11 Univ Aarhus SELECTIVE EXOSITE INHIBITATION OF PAPP-A ACTIVITY AGAINST IGFBP-4
CN104940928B (zh) 2008-12-05 2018-03-30 阿布拉西斯生物科学有限责任公司 结合SPARC的scFv

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04304897A (ja) * 1991-04-01 1992-10-28 Kyowa Hakko Kogyo Co Ltd 抗イディオタイプモノクローナル抗体
DE19627352A1 (de) * 1996-06-27 1998-01-02 Max Delbrueck Centrum Vakzine gegen Kohlenhydrat-Antigene
WO1999040433A1 (en) * 1998-02-04 1999-08-12 The Trustees Of The University Of Pennsylvania Peptide mimotopes of carbohydrate antigens
GB9808327D0 (en) * 1998-04-20 1998-06-17 Chiron Spa Antidiotypic compounds

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US8642276B2 (en) * 2002-07-22 2014-02-04 Glycotope Gmbh Method for the production of an immunostimulating mucin (MUC1)
US9487567B2 (en) 2002-07-22 2016-11-08 Glycotope Gmbh Method for the production of an immunostimulating mucin (MUC1)
US20140206021A1 (en) * 2002-12-03 2014-07-24 North Carolina State University Prion protein ligands and methods of use
US9678085B2 (en) * 2002-12-03 2017-06-13 Pathogen Removal And Diagnostic Technologies Inc. Prion protein ligands and methods of use
US8030025B2 (en) 2008-02-20 2011-10-04 Amgen Inc. Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
US8221749B2 (en) 2008-02-20 2012-07-17 Amgen Inc. Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
US10336820B2 (en) 2008-02-20 2019-07-02 Amgen Inc. Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof

Also Published As

Publication number Publication date
DE10027695A1 (de) 2001-04-19
WO2000073430A2 (de) 2000-12-07
EP1181058A2 (de) 2002-02-27
AU6424300A (en) 2000-12-18
WO2000073430A3 (de) 2001-03-29

Similar Documents

Publication Publication Date Title
CA2375033A1 (en) Vaccines against conformation-dependent antigens and against antigens that are not or are not only proteins or peptides
Apostolopoulos et al. Murine immune response to cells transfected with human MUC1: immunization with cellular and synthetic antigens
EP0804231B1 (de) Synthetische, vielfache tandemwiederholungen des mucinpeptides und seiner derivate und deren verwendung
US6344203B1 (en) Mimicking peptides in cancer therapy
US7854931B2 (en) Immunizing compostion and method for inducing an immune response against the beta-secretase cleavage site of amyloid precursor protein
CA2468259C (en) Antibody to latent membrane proteins and uses thereof
CZ294425B6 (cs) Způsob výroby anti-humánního antigenového receptoru, anti-humánní antigenový receptor, řetězec VH a VL, souprava pro selekci anti-humánních antigenových receptorů a farmaceutická kompozice, obsahující uvedený receptor
AU2006228067A1 (en) Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
Manoutcharian et al. Phage displayed biomolecules as preventive and therapeutic agents
CA2253602A1 (en) Method and composition for reconforming multi-epitopic antigens to initiate an immune response
US6656481B1 (en) Vaccinal preparations
RU2322260C2 (ru) Пассивная иммунизационная терапия на основе пептидов для лечения атеросклероза
MXPA01007148A (es) Uso de anticuerpos para vacunacion anti-cancer.
AU2018359358B2 (en) Nano-particles that contain synthetic variants of GM3 ganglioside as adjuvants in vaccines
JPWO2020206330A5 (de)
Vichier‐Guerre et al. Short synthetic glycopeptides successfully induce antibody responses to carcinoma‐associated Tn antigen
WO2001081371A1 (fr) Peptides gd3 mimetiques
Ježek et al. Solid phase synthesis of glycopeptide dendrimers with Tn antigenic structure and their biological activities. Part I
JP2002533357A (ja) 疾病の治療に有用なペプチドミミック
JP5534630B2 (ja) Ｇｄ３模倣ペプチド
KR100372958B1 (ko) 면역반응을개시시키기위해다중에피토프항원의입체형태를변화시키기위한방법및조성물
AU711270C (en) Method and composition for reconforming multi-epitopic antigens to initiate an immune response
JP2000511764A (ja) マウスモノクローナル抗イディオタイプ抗体１１ｄ１０およびその使用方法
Cramer Book Review: The Importance of Antibody Pathways for the Rejection of Xenografts: An Immunological Conundrum?
Apostolopoulos et al. Murine Immune Response to Cells Transfected with Human MUC1: Immunization

Legal Events

Date Code Title Description
FZDE Dead